Johnson & Johnson (JNJ) EPS (Basic) Growth (3y) (2012 - 2026)

Johnson & Johnson (JNJ) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) Growth (3y) (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 76.94%
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 137.44%
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 109.43%
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 121.20%
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -51.68%
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -14.13%
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 27.32%
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -145.91%
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -7.59%

Historic Data

Download Data
DateValue
Mar 29, 2026 137.44%
Dec 28, 2025 167.03%
Sep 28, 2025 236.15%
Jun 29, 2025 122.14%
Mar 30, 2025 174.94%
Dec 31, 2023 -27.03%
Oct 1, 2023 85.44%
Jul 2, 2023 -27.34%
Apr 2, 2023 -58.06%
Jan 1, 2023 -58.09%
Oct 2, 2022 -56.09%
Jul 3, 2022 -53.69%
Apr 3, 2022 -46.16%
Oct 3, 2021 -1.69%
Jul 4, 2021 17.39%
Apr 4, 2021 13.09%
Jan 3, 2021 29.38%
Sep 27, 2020 -1.25%
Jun 28, 2020 -1.05%
Mar 29, 2020 10.44%